References
1. Ananthapanyasut W, Napan S, Rudolph EH, et al. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(2):173-181. doi: 10.2215/CJN.03170509.
2. Soliman EZ, Prineas RJ, Go AS, et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010;159(6):1102-1107. doi: 10.1016/j.ahj.2010.03.027.
3. Baber U, Howard VJ, Halperin JL, et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.Circ Arrhythm Electrophysiol. 2011;4(1):26-32. doi: 10.1161/CIRCEP.110.957100.
4. Mitsuma W, Matsubara T, Hatada K, et al. Clinical characteristics of hemodialysis patients with atrial fibrillation: The RAKUEN (Registry of atrial fibrillation in chronic kidney disease under hemodialysis from Niigata) study. J Cardiol. 2016;68(2):148-155. doi: 10.1016/j.jjcc.2015.08.023.
5. Bonde AN, Lip GY, Kamper AL, et al. Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation: An Observational Cohort Study. Stroke. 2016;47(11):2707-2713. doi: 10.1161/strokeaha.116.014422.
6. Providência R, Marijon E, Boveda S, et al. Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation. Am J Cardiol.2014;114(4):646-653. doi: 10.1016/j.amjcard.2014.05.048.
7. Andrade JG, Aguilar M, Atzema C, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2020;36(12):1847-1948. doi: 10.1016/j.cjca.2020.09.001.
8. Marzec LN, Wang J, Shah ND, et al. Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation.J Am Coll Cardiol. 2017;69(20):2475-2484. doi: 10.1016/j.jacc.2017.03.540.
9. Haas S, Camm AJ, Bassand JP, et al. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. Am Heart J.2019;213:35-46. doi: 10.1016/j.ahj.2019.03.013.
10. Bohula EA, Giugliano RP, Ruff CT, et al. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.Circulation. 2016;134(1):24-36. doi: 10.1161/CIRCULATIONAHA.116.022361.
11. Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.Eur Heart J. 2011;32(19):2387-2394. doi: 10.1093/eurheartj/ehr342.
12. Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation. Circulation.2014;129(9):961-970. doi: 10.1161/CIRCULATIONAHA.113.003628.
13. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22):2821-2830. doi: 10.1093/eurheartj/ehs274.
14. Chen H-Y, Ou S-H, Huang C-W, et al. Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis. Clin Drug Investig. 2021;41(4):341-351. doi: 10.1007/s40261-021-01016-7.
15. Di Lullo L, Tripepi G, Ronco C, et al. Safety and effectiveness of rivaroxaban and warfarin in moderate-to-advanced CKD: real world data.J Nephrol. 2018;31(5):751-756. doi: 10.1007/s40620-018-0501-7.
16. Siontis KC, Zhang X, Eckard A, et al. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation.2018;138(15):1519-1529. doi: 10.1161/CIRCULATIONAHA.118.035418.
17. Makani A, Saba S, Jain SK, et al. Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin in Patients With Chronic Kidney Disease and Atrial Fibrillation. Am J Cardiol. 2020;125(2):210-214. doi: 10.1016/j.amjcard.2019.10.033.
18. Schafer JH, Casey AL, Dupre KA, Staubes BA. Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease. Ann Pharmacother. 2018;52(11):1078-1084. doi: 10.1177/1060028018781853.
19. Coleman CI, Kreutz R, Sood NA, et al. Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis. Am J Med. 2019;132(9):1078-1083. doi: 10.1016/j.amjmed.2019.04.013.
20. Loo SY, Coulombe J, Dell’Aniello S, Brophy JM, Suissa S, Renoux C. Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study. BMJ Open. 2018;8(1):e019638. doi: 10.1136/bmjopen-2017-019638.
21. Shin JI, Secora A, Alexander GC, et al. Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation. Clin J Am Soc Nephrol. 2018;13(8):1144-1152. doi: 10.2215/CJN.13811217.
22. Liabeuf S, Laville SM, Bieber B, et al. Prescription of Direct Oral Anticoagulants to Patients With Moderate-to-Advanced CKD: Too Little or Just Right? Kidney Int Rep. 2021;6(9):2496-2500. doi: 10.1016/j.ekir.2021.06.004.
23. Wetmore JB, Roetker NS, Yan H, Reyes JL, Herzog CA. Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillation. Stroke.2020;51(8):2364-2373. doi: 10.1161/STROKEAHA.120.028934.
24. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495-1499. doi: 10.1016/j.ijsu.2014.07.013.
25. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol. 1995;48(8):999-1009. doi: 10.1016/0895-4356(94)00234-h.
26. Eguale T, Winslade N, Hanley JA, Buckeridge DL, Tamblyn R. Enhancing pharmacosurveillance with systematic collection of treatment indication in electronic prescribing: a validation study in Canada. Drug Saf. 2010;33(7):559-567. doi: 10.2165/11534580-000000000-00000.
27. Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol.2004;57(2):131-141. doi: 10.1016/S0895-4356(03)00246-4.
28. Tamblyn R, Reid T, Mayo N, McLeod P, Churchill-Smith M. Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment. J Clin Epidemiol. 2000;53(2):183-194. doi: 10.1016/s0895-4356(99)00136-5.
29. Humphries KH, Jackevicius C, Gong Y, et al. Population rates of hospitalization for atrial fibrillation/flutter in Canada. Can J Cardiol. 2004;20(9):869-876. doi:
30. Perreault S, Shahabi P, Cote R, et al. Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study. Clin Cardiol. 2018. doi: 10.1002/clc.22948.
31. Roy L, Zappitelli M, White-Guay B, Lafrance JP, Dorais M, Perreault S. Agreement Between Administrative Database and Medical Chart Review for the Prediction of Chronic Kidney Disease G category. Can J Kidney Health Dis. 2020;7:2054358120959908. doi: 10.1177/2054358120959908.
32. Blais C LL, Hamel D, Brown K, Rinfret S, Cartier R, Giguère M, Carroll C, Beauchamp C, Bogaty P. Évaluation des soins et surveillance des maladies cardiovasculaires de santé publique du Québec et de L’institut national d’excellence en santé et services sociaux.Gouvernement du Québec, Institut national de santé publique , Institut national d’excellence en santé et des services sociaux.2012:1-9. doi:
33. Levy AR, Tamblyn RM, Fitchett D, McLeod PJ, Hanley JA. Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. Can J Cardiol. 1999;15(11):1277-1282. doi:
34. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol.1992;45(6):613-619. doi: 10.1016/0895-4356(92)90133-8.
35. D’Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases.J Clin Epidemiol. 1996;49(12):1429-1433. doi: 10.1016/s0895-4356(96)00271-5.
36. Crane SJ, Tung EE, Hanson GJ, Cha S, Chaudhry R, Takahashi PY. Use of an electronic administrative database to identify older community dwelling adults at high-risk for hospitalization or emergency department visits: the elders risk assessment index. BMC Health Serv Res.2010;10:338. doi: 10.1186/1472-6963-10-338.
37. Fillion V, Sirois MJ, Gamache P, Guertin JR, Morin SN, Jean S. Frailty and health services use among Quebec seniors with non-hip fractures: a population-based study using adminsitrative databases.BMC Health Serv Res. 2019;19(1):70. doi: 10.1186/s12913-019-3865-z.
38. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.Stat Med. 2015;34(28):3661-3679. doi: 10.1002/sim.6607.
39. Allan V, Ramagopalan SV, Mardekian J, et al. Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants. J Comp Eff Res. 2020;9(9):603-614. doi: 10.2217/cer-2020-0013.
40. VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann Intern Med.2017;167(4):268-274. doi: 10.7326/M16-2607.
41. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.
42. Fu CM, Li LC, Lee YT, Wang SW, Hsu CN. Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease. Front Cardiovasc Med. 2021;8. doi: 10.3389/fcvm.2021.752468.
43. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med.2011;365(10):883-891. doi: 10.1056/NEJMoa1009638.
44. Yao X, Tangri N, Gersh BJ, et al. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol.2017;70(21):2621-2632. doi: 10.1016/j.jacc.2017.09.1087.
45. Koos R, Mahnken AH, Muhlenbruch G, et al. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol.2005;96(6):747-749. doi: 10.1016/j.amjcard.2005.05.014.
46. Shea MK, O’Donnell CJ, Hoffmann U, et al. Vitamin K supplementation and progression of coronary artery calcium in older men and women.Am J Clin Nutr. 2009;89(6):1799-1807. doi: 10.3945/ajcn.2008.27338.
47. Schurgers LJ, Aebert H, Vermeer C, Bultmann B, Janzen J. Oral anticoagulant treatment: friend or foe in cardiovascular disease?Blood. 2004;104(10):3231-3232. doi: 10.1182/blood-2004-04-1277.
48. Elango K, Javaid A, Khetarpal BK, et al. The Effects of Warfarin and Direct Oral Anticoagulants on Systemic Vascular Calcification: A Review.Cells. 2021;10(4):773. doi: 10.3390/cells10040773.